To overcome resistance and enhance antitumor immunity, we rationally engineered the tumor-activated prodrug H62, which combines a potent DHODH inhibitor (EA6) with a validated STING agonist (MSA) via a protease-cleavable linker. This evidence concerns the gene STING1 and neoplasm.